Name: Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry (Video) | JoVE Journal
Uploaded: 2023-10-06T12:00:00.000+00:00
Duration: 7 min 29 s
Description: Learn flow cytometry methods to track microRNA release into extracellular vesicles using Calu-6 cells. This protocol captures dynamic RNA packaging mechanisms relevant to cancer biology research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

We acknowledge support and advice from Dr. Jill Hutchcroft, Director of the Flow Cytometry Core Facility at Purdue University. This work was supported by R01CA226259 and R01CA205420 to A.L.K., an American Lung Association Innovation Award (ANALA2023) IA-1059916 to A.L.K., a Purdue Shared resource facility grant P30CA023168, and a flagship Fulbright Doctoral Scholarship awarded by the Department of the State, USA to H.H.

NOTE: As a prerequisite to using this technique, identification and validation of selectively exported miRNAs is required. Since different cell lines vary based on the miRNA cargo sorted into their EVs, it is recommended that the cell line of interest and associated EVs be evaluated for miRNAs prior to use. Additionally, lipofectamine-based transfection is one of the critical steps in the protocol; predetermining transfection efficiency prior to setting up the experiment is recommended.
1. Growing cells in culture and transfecting cells with fluorophore-conjugated EV-miRNA
<ol>
	<li>Plate 200,000 to 400,000 cells in triplicate wells in a 6-well plate in an appropriate culture medium. Gently swirl the plate to ensure uniform cell distribution. Incubate the cells until they reach 70%-80% confluency, approximately 24-48 h.</li>
	<li>For each well to be transfected, dilute the transfection reagent in 100&#181;L of serum-free medium in a microcentrifuge tube according to the manufacturer&#39;s instructions. 
	NOTE: The optimal concentration of lipid should be determined for the cell line of interest prior to this setup.</li>
	<li>For each well to be transfected, dilute the fluorophore-conjugated EV-miRNA (2nM) and cell-miRNA (2nM) separately in a microcentrifuge tube in 100 &#181;L of serum-free media. 
	NOTE: The total volume should be calculated for the total number of wells transfected. In this protocol, the fluorescence was evaluated at 7 time points; therefore, the total volume was 700 &#181;L for step 1.2 and 700 &#181;L for step 1.3. Additionally, to confidently capture the positive fluorescent population of cells, the user should transfect cells with a non-fluorescent scrambled miRNA and set up a gate excluding these cells.</li>
	<li>Add the diluted RNA mix (from step 1.3) to the diluted transfection reagent (from step 1.2) and mix gently by inverting the tube 3-4 times. Let the combined lipid-RNA mix incubate for 30 min at room temperature (RT).</li>
	<li>Remove the regular culture media from the cells and add 800 &#181;L of serum-free media to each well. Gently add 200 &#181;L of the lipid-RNA mix (from step 1.4) dropwise to the cells. 
	NOTE: Opti-MEM media was used for transfecting the cell line of interest (Calu6 cells). Try to add the lipid-RNA mix directly to the culture media, avoiding adding the mixture to the sides of the plate.</li>
</ol>
2. Harvesting transfected cells at various time points for analysis of fluorescence
<ol>
	<li>Incubate the transfected cells at 37 &#176;C for 7 h. 
	NOTE: To validate consistent transfection of both miRNAs (EV-miRNA and cell-miRNA), cells are collected from one well 3 h post-transfection to analyze the fluorescence using the flow cytometer.</li>
	<li>After the 7 h incubation period, remove the transfection complex from the wells and replace it with complete media.</li>
	<li>To evaluate the 7-h time-point, harvest the cells and wash the cells three times with 1x PBS.
	<ol>
		<li>If working with adherent cells, add 200 &#181;L of trypsin to one well and wait for the cells to detach from the plate. Transfer the detached cells to a microcentrifuge tube and pellet by centrifugation at 200xg for 5 min.</li>
		<li>Discard the supernatant carefully to avoid disrupting the cell pellet. For the first PBS wash, resuspend the pellet in ~500 &#181;L of 1x PBS and repeat the pelleting using the centrifugation steps above. Repeat the PBS wash an additional two times.</li>
		<li>Resuspend the cell pellet in 200 &#181;L of 2% paraformaldehyde (PFA) solution and evaluate fluorescence. 
		NOTE: After adding 2% PFA, the cell pellet can be stored at 4 &#176;C for 3-4 days. </li>
	</ol>
	</li>
	<li>Harvest the remaining time points following the steps in section 2.3. Collect all of the stored cell pellets and proceed with the steps in section 3.</li>
</ol>
3. Flow cytometry analysis of cell-miRNA and EV-miRNA signal in cells
<ol>
	<li>Prepare cells for flow cytometry analysis. Filter the cell suspension from section 2 through 35 &#181;m strainer caps that are part of the round bottom polystyrene FACS tubes to enable the removal of debris and cell aggregates that might interfere with fluorophore analysis.</li>
	<li>Set up the instrument following calibration instructions. Turn on the flow cytometer and allow it to warm up for at least 30 min before use. Prime the fluidics system with sheath fluid, and check and adjust the laser alignment.</li>
	<li>Run quality control to confirm instrument fluidics. Load ultrapure&#160;filtered water into the flow cytometer and run at an appropriate flow rate for adequate acquisition time. 
	NOTE: The appropriate flow rate and acquisition time will depend on the cell type of interest, sample complexity, and desired data quality.</li>
	<li>Open the flow cytometry data analysis software and confirm the performance of the detector and lasers. Set up threshold and voltage parameters for detection based on the cell line of interest and fluorophores of choice. 
	NOTE: For all downstream experiments, Calu6 cells were used.
	<ol>
		<li>Set the threshold for capturing the signal for Calu6 cells at FSC 5000. Perform the analysis for 1 x 104 cells for each experimental repeat.</li>
		<li>To account for the spectral overlap between different fluorophores, use un-transfected cells and cells independently transfected with only one of the fluorophores to set up compensation controls.</li>
		<li>For detection of miRNA export, use candidate EV-miRNAs (miR-451a and miR-150) conjugated to Alexa-fluor 488, and a control cell-miRNA (cel-miR-67) conjugated to Cy3.</li>
		<li>For each EV-miRNA, conjugate the fluorophore to the 5&#8242; end of the 5p strand. Before transfection, anneal the fluorophore-conjugated strand to its 100% complementary 3p strand.</li>
		<li>For the expression analysis in transfected cells, analyze the samples using the FSC, SSC, FITC, and PE channels set to 258, 192, 269, and 423 voltage units, respectively (Figure 1A, B).</li>
	</ol>
	</li>
	<li>Introduce the negative control sample into the flow cytometer. Capture cell signals after defining forward scatter (FSC) and side scatter (SSC) intensities in a custom worksheet.</li>
	<li>In the plot, choose FSC for the X-axis, SSC for the Y-axis, and gate for the population of interest by drawing a polygon around it (see Figure 1B, bottom panel).</li>
	<li>Create a new plot using the gated population.
	<ol>
		<li>Set the X-axis to fluorescence signal 1 (FS1) for cell-miRNA detection and the Y-axis to fluorescence signal 2 (FS2) for EV-miRNA detection. Set up compensation parameters for the individual fluorophores using cells independently transfected with each of the fluorescently tagged miRNAs. In the new plot, gate on the population of interest.</li>
		<li>For detection of EV-miRNA, use the FITC channel. For the evaluation of cell-miRNA signal, use the PE channel. In the software, create a gate around the cells that were positive for both FITC and PE by drawing a polygon around the double fluorescence population when FITC was selected for the X-axis and PE was selected for the Y-axis.</li>
	</ol>
	</li>
	<li>Record the statistics for the gated population.
	<ol>
		<li>Record the percentage of cells in the gated population that are positive for both FITC and PE, as well as for those that are positive for either FITC or PE.</li>
	</ol>
	</li>
	<li>Repeat the above steps for any additional samples or controls in the experiment.</li>
</ol>
4. Isolating EVs from transfected cells
<ol>
	<li>For cells cultured in serum-containing media, deplete EVs from the serum to prevent cross-contamination.
	<ol>
		<li>To generate EV-depleted serum, dilute the serum to 50% in cell culture media to reduce viscosity and centrifuge the resulting 50% serum at 110,000 x g for 18 h.</li>
		<li>Collect the supernatant (EV-free serum) carefully and filter it using a 0.2 &#181;m filter assembly. Use the resulting 50% EV-free serum to generate complete media, in this case, RPMI plus 10% serum.</li>
		<li>To collect EVs, add the EV-depleted complete media to the cells and collect the EVs 48 h after incubation. 
		NOTE: The protocol outlined below has been modified from Kowal et al.14.</li>
	</ol>
	</li>
	<li>Grow cells in 15 cm tissue culture dishes to 80% confluency. Transfect the cells separately with cell-miRNA and EV-miRNA in 10 mL of Opti-MEM following the transfection protocol in section 1 of the protocol. 
	NOTE: Not all transfection protocols scaleup linearly. It may be essential to first adapt and evaluate the transfection conditions in 15 cm plates.</li>
	<li>After 7 h, aspirate the transfection media and replace it with the EV-depleted media (15 mL). Grow cells in the EV-depleted media for 48 h.</li>
	<li>Remove the conditioned media from the cells and dispense it into a 50 mL centrifuge tube inside the biosafety cabinet. Centrifuge the conditioned media at 2000 x g for 10 min at 4 &#176;C to remove dead cells and cell debris. Transfer the resulting supernatant to a fresh tube.</li>
	<li>Centrifuge the supernatant at 10,000 x g for 40 min at 4 &#176;C. Remove the supernatant and filter it using a 0.2 &#181;m filter assembly.</li>
	<li>Transfer the filtered cell culture media to a sterile ultracentrifuge tube inside the biosafety cabinet. Weigh and balance the tubes against each other. Spin the samples at 110,000 x g for 90 min at 4 &#176;C. Discard the supernatant.</li>
	<li>Resuspend the pellet in an appropriate volume of 1x PBS to wash and centrifuge at 110,000 x g for 90 min 4 &#176;C. 
	NOTE: The EV pellet was resuspended in 60 mL of 1x PBS based on the maximum volume allowed for the fixed-angle rotor tubes used in this study.</li>
	<li>Aspirate PBS and suspend the EV pellet in an appropriate volume (50-100 &#181;L) of fresh 1x PBS and vortex. Store EVs at -80 &#176;C for later use.</li>
</ol>
5. Flow cytometry analysis of cell-miRNA and EV-miRNA signal in EVs
<ol>
	<li>To prepare EV suspension for flow cytometry analysis, dilute EVs in an appropriate volume of ultrafiltered 1x PBS. 
	NOTE: The loading volume for the flow cytometry analysis of EVs should be determined based on the number of EVs in samples. Roughly, if there are ~30,000 particles in the EV suspension, the final volume should be ~500-600 &#181;L in 1x PBS. A clean sample has around 35-50 particles/&#181;L.</li>
	<li>Use the nano-flow cytometer or an alternative equipment powerful enough to analyze nano-sized particles. 
	NOTE: Here, Attune NxT nano-flow cytometer was used.</li>
	<li>Open the software and set the instrument up following the recommended calibration instructions. Perform the Performance Test using performance nano-beads. If the nano-beads are detected in the standard size range, the performance is optimal. Determine the appropriate flow rate for the detection of EV particles.</li>
	<li>Run quality control using ultrapure filtered water to confirm instrument fluidics and performance of detector and lasers.</li>
	<li>Using calibration beads suitable for the experiment, set the flow cytometer to accurately detect different-sized beads and measure fluorescence signals. 
	NOTE: For the setup of EV analysis by flow cytometry, ApogeeMix beads were used. These beads contain a mixture of non-fluorescent silica beads and fluorescent polystyrene beads ranging in sizes from 80 nm to 1300 nm.
	<ol>
		<li>Set up the parameters to assess the sensitivity and resolution of different populations in the bead mix according to the manufacturer&#39;s protocol. Use the appropriate gating to resolve the bead population from the instrument noise.</li>
	</ol>
	</li>
	<li>Vortex the samples thoroughly to evenly distribute EVs before loading for analysis.</li>
	<li>Open the flow cytometry data analysis software and introduce ultra-filtered PBS. Set the gating up for EV particles using ultra-filtered PBS while ensuring that the gating corresponds to the appropriate size of particles based on the beads in step 5.5.</li>
	<li>Load the negative control sample to analyze EVs as they pass through the flow cytometer. Capture EV signals while plotting FSC on the X-axis and SSC on the Y-axis. 
	NOTE: The SSC threshold for capturing EVs was set at 300. The acquisition volume was set at 95 &#181;L from a total of 145 &#181;L drawn volume. The flow rate was set at 12.5 &#181;L/min. The analysis was performed with 1 x 106 EV particles. The EV population is heterogeneous and will result in some debris isolated along with EVs. Overall particle detection in the FSC vs. SSC plot highlights particles in a diverse range, which is expected when using crude EV preparations.</li>
	<li>Create a new plot using the gated population.
	<ol>
		<li>This time, choose fluorescence signal 1 (FS1) for cell-miRNA detection on the X-axis and fluorescence signal 2 (FS2) for EV-miRNA detection on the Y-axis.</li>
		<li>Set up compensation parameters for the fluorophores using the EV samples isolated from cells transfected with a single miRNA. In the new plot, gate on the EV population of interest.</li>
		<li>For the expression analysis of fluorophore-conjugated miRNAs in EVs isolated from the transfected cells, analyze the EV samples using the FSC, SSC, BL1, and YL1 channels set to 370, 370, 400, and 400 voltage units, respectively (Figure 2A, B).</li>
		<li>Record the statistics for the gated population and visualize them using histograms and dot plots.</li>
	</ol>
	</li>
	<li>Repeat the above steps for any additional samples or controls in the experiment.</li>
</ol>
6. Validating the release of miRNAs in EVs through qRT-PCR
<ol>
	<li>Extract RNA from EVs and parent cells using miRVana RNA isolation kit following the manufacturer&#39;s instructions. 
	NOTE: Quantification of RNA isolated from EVs is not possible because the total amount of RNA isolated from EVs does not typically cross the minimal quantity threshold of a standard Nano-drop. This is due to the depletion of ribosomal RNA from EV samples, which can be validated using the Agilent Bioanalyzer. Thus, the integrity score for EV-RNA quantification is usually not reliable and is not the true representation of EV-RNA quantity. Therefore, for qRT-PCR quantification of the EV-RNA and cell-RNA, equal volumes of RNA isolates following isolation from an equal number of cells were used. For normalization of qRT-PCR, miRNAs ubiquitously present across multiple samples as determined from previously acquired RNA sequencing data were used.</li>
	<li>Convert the extracted RNA to cDNA using a reverse transcriptase kit specific for small RNAs.</li>
	<li>Set up the qRT-PCR reaction using a cDNA template and miRNA-specific primers following the manufacturer&#39;s instructions. 
	NOTE: For validation experiments, miRCURY LNA qRT PCR kit and corresponding primers from the manufacturer were used to evaluate the expression of cell-miRNA and EV-miRNA.</li>
</ol>

A Flow Cytometry Protocol for Understanding Export Mechanisms

<ol><li>Kasinski, A. L., Slack, F. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((MicroRNAs+en+route+to+the+clinic%3A+Progress+in+validating+and+targeting+microRNAs+for+cancer+therapy%5BTitle%5D)+AND+%22Nature+Reviews+Cancer%22%5BJournal%5D)">MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy.</a> Nature Reviews Cancer. 11 (12), 849-864 (2011).</li>
<li>Treiber, T., Treiber, N., Meister, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regulation+of+microRNA+biogenesis+and+its+crosstalk+with+other+cellular+pathways%5BTitle%5D)+AND+%22Nature+Reviews+Molecular+Cell+Biology%22%5BJournal%5D)">Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.</a> Nature Reviews Molecular Cell Biology. 20 (1), 5-20 (2019).</li>
<li>Lu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((MicroRNA+expression+profiles+classify+human+cancers%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">MicroRNA expression profiles classify human cancers.</a> Nature. 435 (7043), 834-838 (2005).</li>
<li>Orellana, E., Tenneti, S., Rangasamy, L., Lyle, L., Low, P., Kasinski, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((FolamiRs%3A+Ligand-targeted%2C+vehicle-free+delivery+of+microRNAs+for+the+treatment+of+cancer%5BTitle%5D)+AND+%22Science+Translational+Medicine%22%5BJournal%5D)">FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.</a> Science Translational Medicine. 9 (401), eaam9327(2017).</li>
<li>Orellana, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enhancing+microRNA+activity+through+increased+endosomal+release+mediated+by+nigericin%5BTitle%5D)+AND+%22Molecular+Therapy-+Nucleic+Acids%22%5BJournal%5D)">Enhancing microRNA activity through increased endosomal release mediated by nigericin.</a> Molecular Therapy- Nucleic Acids. 16, 505-518 (2019).</li>
<li>Abdelaal, A. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+first-in-class+fully+modified+version+of+miR-34a+with+outstanding+stability%2C+activity%2C+and+anti-tumor+efficacy%5BTitle%5D)+AND+%22Oncogene%22%5BJournal%5D)">A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.</a> Oncogene. , (2023).</li>
<li>Crescitelli, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Distinct+RNA+profiles+in+subpopulations+of+extracellular+vesicles%3A+Apoptotic+bodies%2C+microvesicles+and+exosomes%5BTitle%5D)+AND+%22Journal+of+Extracellular+Vesicles%22%5BJournal%5D)">Distinct RNA profiles in subpopulations of extracellular vesicles: Apoptotic bodies, microvesicles and exosomes.</a> Journal of Extracellular Vesicles. 2, (2013).</li>
<li>Hasan, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Extracellular+vesicles+released+by+non-small+cell+lung+cancer+cells+drive+invasion+and+permeability+in+non-tumorigenic+lung+epithelial+cells%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.</a> Scientific Reports. 12 (1), 972(2022).</li>
<li>Costa-Silva, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pancreatic+cancer+exosomes+initiate+pre-metastatic+niche+formation+in+the+liver%5BTitle%5D)+AND+%22Nature+Cell+Biology%22%5BJournal%5D)">Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.</a> Nature Cell Biology. 17 (6), 816-826 (2015).</li>
<li>Villarroya-Beltri, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sumoylated+hnRNPA2B1+controls+the+sorting+of+miRNAs+into+exosomes+through+binding+to+specific+motifs%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs.</a> Nature Communications. 4, 2980(2013).</li>
<li>Cha, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((KRAS-dependent+sorting+of+miRNA+to+exosomes%5BTitle%5D)+AND+%22elife%22%5BJournal%5D)">KRAS-dependent sorting of miRNA to exosomes.</a> elife. 4, e07197(2015).</li>
<li>Gandham, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Technologies+and+standardization+in+research+on+extracellular+vesicles%5BTitle%5D)+AND+%22Trends+in+Biotechnology%22%5BJournal%5D)">Technologies and standardization in research on extracellular vesicles.</a> Trends in Biotechnology. 38 (10), 1066-1098 (2020).</li>
<li>Théry, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Minimal+information+for+studies+of+extracellular+vesicles+2018+%28MISEV2018%29%3A+a+position+statement+of+the+International+Society+for+Extracellular+Vesicles+and+update+of+the+MISEV2014+guidelines%5BTitle%5D)+AND+%22Journal+of+Extracellular+Vesicles%22%5BJournal%5D)">Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.</a> Journal of Extracellular Vesicles. 7 (1), 1535750(2018).</li>
<li>Kowal, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Proteomic+comparison+defines+novel+markers+to+characterize+heterogeneous+populations+of+extracellular+vesicle+subtypes%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.</a> Proceedings of the National Academy of Sciences of the United States of America. 113 (8), E968-E977 (2016).</li>
<li>Sork, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Heterogeneity+and+interplay+of+the+extracellular+vesicle+small+RNA+transcriptome+and+proteome%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome.</a> Scientific Reports. 8 (1), 10813(2018).</li>
<li>Mittelbrunn, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Unidirectional+transfer+of+microRNA-loaded+exosomes+from+T+cells+to+antigen-presenting+cells%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells.</a> Nature Communications. 2, 282(2011).</li>
<li>Chiou, N. T., Kageyama, R., Ansel, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Selective+export+into+extracellular+vesicles+and+function+of+tRNA+fragments+during+T+cell+activation%5BTitle%5D)+AND+%22Cell+Reports%22%5BJournal%5D)">Selective export into extracellular vesicles and function of tRNA fragments during T cell activation.</a> Cell Reports. 25 (12), 3356-3370 (2018).</li>
<li>Guzewska, M. M., Witek, K. J., Karnas, E., Rawski, M., Zuba-Surma, E., Kaczmarek, M. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((miR-125b-5p+impacts+extracellular+vesicle+biogenesis%2C+trafficking%2C+and+EV+subpopulation+release+in+the+porcine+trophoblast+by+regulating+ESCRT-dependent+pathway%5BTitle%5D)+AND+%22The+FASEB+Journal%22%5BJournal%5D)">miR-125b-5p impacts extracellular vesicle biogenesis, trafficking, and EV subpopulation release in the porcine trophoblast by regulating ESCRT-dependent pathway.</a> The FASEB Journal. 37 (8), e23054(2023).</li>
</ol>

The authors have nothing to disclose.

The newly established protocol enables capturing kinetics of miRNA release into EVs post-transfection of EV-miRNAs. The approach allows simultaneous analysis of multiple EV-miRNAs and cell-miRNAs, subject to the capabilities of the cytometer. Moreover, while flow cytometry analysis can provide valuable insights into EV miRNA biology, it is not without limitations. Albeit some of the limitations can be overcome when used in conjunction with other techniques for a more comprehensive understanding. 
<p class="jove_conte...

MicroRNAs (miRNAs) are one of the best-characterized subsets of small noncoding RNAs, which are known for their critical role in post-transcriptional gene regulation. The expression and biogenesis of most miRNAs follow a coordinated series of events that begins with transcription of the primary miRNAs (pri-miRNAs) in the nucleus. Following nuclear processing by the microprocessor complex into precursor-miRNAs (pre-miRNAs), the pre-miRNAs are exported to the cytoplasm, where they undergo further processing by the RNase III endonuclease, dicer into 21-23 nucleotide mature miRNA duplexes1. One of the strands of the processed mature miRNA binds to target messenger RNAs (mRNAs), leading to degradation or translational repression of the targets2. Based on the pleiotropic role of miRNAs in simultaneously regulating multiple diverse target mRNAs, it is not surprising that miRNA expression is tightly regulated3. Indeed, inappropriate expression contributes to various disease states, especially in cancer. The aberrant expression of miRNAs not only represents a disease-specific signature but has also emerged as a target for prognostic and therapeutic potential4,5,6. In addition to their intracellular roles, miRNAs also have non-autonomous roles. For example, miRNAs can be selectively packaged into EVs by donor cells and exported to recipient sites where they elicit diverse phenotypic responses in normal and disease physiology7,8,9.
Despite clear evidence that EV-associated miRNAs are functional biomolecules, it is not completely understood how specific subsets of miRNAs are dysregulated in disease states such as cancer and how cellular machinery selects and sorts miRNAs into Evs10,11. Given the potential role of EV-miRNAs in modulating the microenvironment, it is critical to identify the mechanisms involved in the export of select miRNAs to fully elucidate the role of EVs in intercellular communication and disease pathogenesis. Understanding the process of miRNA release into EVs will not only highlight important mediators of miRNA export but can also provide insights into potential therapeutics. To achieve this level of knowledge, tools need to be adapted to faithfully address these new experimental questions. Indeed, studies that evaluate EVs are growing exponentially due to the introduction of new techniques and controls12,13. In relation to evaluating the abundance of exported miRNAs into EVs, next-generation sequencing and quantitative reverse transcription polymerase chain reaction (qRT-PCR) have been the current standard tools. While these tools are useful for evaluating the abundance of miRNAs in EVs, there are limitations to their sensitivity and specificity, and using these static approaches for evaluating dynamics is insufficient. Delineating the dynamics of miRNA export into EVs requires a combination of specialized tools. Here, we present a comprehensive protocol using fluorescently conjugated miRNAs, to analyze the dynamics of miRNA release from donor cells and incorporation into EVs. We also discuss the advantages and limitations of the method and provide recommendations for optimal use. The versatile method presented in this paper will be useful to researchers interested in studying miRNA release into EVs and their potential roles in cellular communication and disease.

<table><tbody><tr><td>1.5 mL microcentrifuge tubes</td><td>Fisher</td><td>05-408-129</td><td></td></tr><tr><td>15 mL Falcon tubes</td><td>Corning</td><td>352097</td><td></td></tr><tr><td>6-well clear flat bottom surface treated tissue culture plates</td><td>Fisher Scientific</td><td>FB012927</td><td></td></tr><tr><td>ApogeeMix 25 mL, (PS80/110/500 &amp;amp; Si180/240/300/590/880/1300 nm)&amp;nbsp;</td><td>Apogee Flow Systems</td><td>1527</td><td>To set up gating and parameters for particle detection&amp;nbsp;</td></tr><tr><td>Attune Nxt Flow Cytometer</td><td>ThermoFisher Scientific</td><td>N/A</td><td>For fluorescence analysis in EVs</td></tr><tr><td>BD Fortessa Cell Analyzer</td><td>BD Biosciences</td><td>N/A</td><td>For fluorescence analysis in cells&amp;nbsp;</td></tr><tr><td>Cell culture incubator</td><td>N/A</td><td>N/A</td><td>Maintaining temperature of 37&amp;nbsp;&amp;deg;C and 5% CO&lt;sub&gt;2&lt;/sub&gt;</td></tr><tr><td>Cell Culture medium</td><td>N/A</td><td>N/A</td><td>specific for the cell-line of interest</td></tr><tr><td>Cell line of interest&amp;nbsp;</td><td>N/A</td><td>N/A</td><td>Any cell line tested and evaluated for EV and cellular abundance of miRNAs on interest.</td></tr><tr><td>Cell-miRNA (miRIDIAN microRNA Mimic Red Transfection Control)</td><td>Horizon discovery</td><td>CP-004500-01-05</td><td>miRNAs predetermined to be retained by the cell-line of interest and not selectively exported out into EVs</td></tr><tr><td>EV-miRNA (Fluorophore conjugated miRNAs)</td><td>Integrated DNA Technologies (IDT)</td><td></td><td>miRNAs predetermined to be selectively sorted into EVs&amp;nbsp;</td></tr><tr><td>Fluorescence microscope</td><td>N/A</td><td>N/A</td><td></td></tr><tr><td>Gibco Opti-MEM Reduced Serum Medium</td><td>Fisher Scientific</td><td>31-985-070</td><td></td></tr><tr><td>Hausser Scientific Hemocytometer</td><td>Fisher</td><td>02-671-54</td><td></td></tr><tr><td>Hyclone 1x PBS (for cell culture)</td><td>Fisher</td><td>SH30256FS</td><td></td></tr><tr><td>Lipofectamine RNAimax</td><td>Fisher Scientific</td><td>13-778-150</td><td></td></tr><tr><td>miRCURY LNA Reverse Transcriptase</td><td>Qiagen</td><td>339340</td><td></td></tr><tr><td>miRCURY LNA SYBR Green PCR</td><td>Qiagen&amp;nbsp;</td><td>339347</td><td></td></tr><tr><td>mirVana RNA Isolation</td><td>Qiagen</td><td>AM1561</td><td></td></tr><tr><td>Nuclease free water</td><td>Fisher Scientific</td><td>4387936</td><td></td></tr><tr><td>Paraformaldehyde, 4% in PBS</td><td>Fisher</td><td>AAJ61899AK</td><td></td></tr><tr><td>Reagent reservoir nonsterile</td><td>VWR</td><td>89094-684</td><td></td></tr><tr><td>Thermo ABI QuantiStudio DX Real-Time PCR</td><td>ThermoFisher Scientific</td><td>N/A</td><td></td></tr><tr><td>Trypsin 0.25%</td><td>Fisher&amp;nbsp;</td><td>SH3004201</td><td></td></tr><tr><td>Ultracentrifuge</td><td>N/A</td><td>N/A</td><td></td></tr></tbody></table>

tracking mirna release into extracellular vesicles using flow cytometry

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Extracellular vesicles (EVs) are important mediators of cellular communication that are secreted by a variety of different cells. These EVs shuttle bioactive molecules, including proteins, lipids, and nucleic acids (DNA, mRNAs, microRNAs, and other noncoding RNAs), from one cell to another, leading to phenotypic consequences in the recipient cells. Of all the various EV cargo, microRNAs (miRNAs) have garnered a great deal of attention for their role in shaping the microenvironment and in educating recipient cells because of their clear dysregulation and abundance in EVs. Additional data indicates that many miRNAs are actively loaded into EVs. Despite this clear evidence, research on the dynamics of export and mechanisms of miRNA sorting is limited. Here, we provide a protocol using flow cytometry analysis of EV-miRNA that can be used to understand the dynamics of EV-miRNA loading and identify the machinery involved in miRNA export. In this protocol, miRNAs predetermined to be enriched in EVs and depleted from donor cells are conjugated to a fluorophore and transfected into the donor cells. The fluorescently tagged miRNAs are then verified for loading into EVs and depletion from cells using qRT-PCR. As both a transfection control and a tool for gating the transfected population of cells, a fluorescently labeled cellular RNA (cell-retained and EV-depleted) is included. Cells transfected with both the EV-miRNA and cell-retained-miRNA are evaluated for fluorescent signals over the course of 72 h. The fluorescence signal intensity specific for the EV-miRNAs diminishes rapidly compared to the cell-retained miRNA. Using this straightforward protocol, one could now assess the dynamics of miRNA loading and identify various factors responsible for loading miRNAs into EVs.

Here, we utilize flow cytometry as a powerful tool to investigate the release of miRNA from the cells into EVs. Using this protocol, flow cytometry analysis of cells transfected with cell-miRNA and EV-miRNA revealed a sequential decrease of fluorescence signal corresponding to EV-miRNA, while the signal corresponding to the cell-miRNA was retained in the cells. To ensure that fluorophore conjugation does not interfere with miRNA release into EVs, miR-451a was conjugated to two separate fluorophores (i.e., Alexa fluor 488...

Here, we describe a straightforward protocol that enables in vitro assessment of the abundance of fluorescently labeled microRNAs to study the dynamics of microRNA packaging and export into extracellular vesicles (EVs).

Extracellular vesicles (EVs) are important mediators of cellular communication that are secreted by a variety of different cells. These EVs shuttle ...

tracking-mirna-release-into-extracellular-vesicles-using-flow

Research

JoVE Journal

Biology

This video demonstrates the immunocapture of extracellular vesicles using fluorescent-labeled capture antibody-magnetic nanoparticle conjugates. The process involves complex formation, staining with fluorescently labeled detection antibodies, magnetic separation, and flow cytometric analysis for antigenic characterization.

Immunocapture and Flow Cytometry of Extracellular Vesicles for Antigenic Characterization

Many different methods exist for the measurement of extracellular vesicles (EVs) using flow cytometry (FCM). Several aspects should be considered when determining the most appropriate method to use. Two protocols for measuring EVs are presented, using either individual detection or a bead-based approach.

Techniques for the Analysis of Extracellular Vesicles Using Flow Cytometry

Viruses or extracellular vesicles were immunocaptured with 15 nm magnetic nanoparticles coupled to antibodies recognizing surface antigens. The captured virions or vesicles were labeled with fluorescent antibodies against other surface antigens. The resultant complexes were separated in high magnetic field and analyzed with conventional flow cytometers triggered on fluorescence.

Flow Virometry to Analyze Antigenic Spectra of Virions and Extracellular Vesicles

Here, we describe the application of three-dimensional fluorescence recovery after photobleaching (3D-FRAP) for the analysis of the gap junction-dependent shuttling of miRNA. In contrast to commonly applied methods, 3D-FRAP allows for the quantification of the intercellular transfer of small RNAs in real time, with high spatio-temporal resolution.

Analysis of the Gap Junction-dependent Transfer of miRNA with 3D-FRAP Microscopy

In this protocol, we describe the complete workflow for rapid isolation of extracellular vesicles from human whole blood and characterization of specific markers by fluorescence-based nanoparticle-tracking analysis. The presented results show a high level of reproducibility and can be adjusted to cell culture supernatants.

Rapid Fluorescence-based Characterization of Single Extracellular Vesicles in Human Blood with Nanoparticle-tracking Analysis

The protocol describes a reproducible method designed for use with cell culture supernatants to detect surface epitopes on small extracellular vesicles (EV). It utilizes specific EV immunoprecipitation using beads coupled with antibodies that recognize surface antigen CD9, CD63, and CD81. The method is optimized for downstream flow cytometry analysis.

Flow Cytometric Analysis of Extracellular Vesicles from Cell-conditioned Media

Extracellular vesicles (EVs) contribute to cellular biology and intercellular communications. There is a need for practical assays to visualize and quantify EVs uptake by the cells. The current protocol proposes the EV uptake assay by utilizing three-dimensional fluorescence imaging via confocal microscopy, following EV isolation by a nano-filtration-based microfluidic device.

Extracellular Vesicle Uptake Assay via Confocal Microscope Imaging Analysis

The latest generation of EV characterization tools are capable of single EV analysis across multiple parameters simultaneously. Nano-flow cytometry measures all biological particles larger than 45 nm without labeling and identifies specific characteristics of subpopulations by a variety of fluorescent labeling techniques.

Single Extracellular Vesicle Transmembrane Protein Characterization by Nano-Flow Cytometry

This protocol provides a detailed description of sorting extracellular vesicles (EVs) released by mesenchymal stromal cells. In particular, it focuses on the instrument setting and the optimization of the sorting conditions. The goal is to sort extracellular vesicles while preserving their characteristics.

Setting a Successful Sorting for Extracellular Vesicle Isolation

Here, we establish a protocol using minimal amounts of fresh-frozen brain tissue sections and an accessible high-speed centrifugation method coupled with size exclusion chromatography to obtain small extracellular vesicles as sources for microRNA (miRNA) biomarkers for neurological disorders.

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Learn flow cytometry methods to track microRNA release into extracellular vesicles using Calu-6 cells. This protocol captures dynamic RNA packaging mechanisms relevant to cancer biology research.

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Explore More Videos